Novel strategies against drug-resistant tuberculosis: a comprehensive review from molecular mechanisms to clinical translation
- 1Institute for Tuberculosis Prevention and Control, Shandong Center for Disease Control and Prevention
- 2Shandong Provincial Key Laboratory of Intelligent Monitoring, Early Warning, Prevention and Control for Infectious Diseases
Abstract
In 2023, an estimated 13% of worldwide deaths resulting from antimicrobial resistance (AMR) were due to drug-resistant TB (DR-TB). The World Health Organization (WHO) documented a dramatic, sixfold increase in the number of patients treated with 6-month all-oral (BPaLM) regimens, from 5,653 patients in 2023, to 34,000 patients by 2024, while also documenting an emergence of bedaquiline resistance in real-world cohorts and a lack of efficacy of BCG revaccination in the BCG-PRIME Phase 2b trial against sustained Mycobacterium tuberculosis infection. Concurrently, the M72/AS01E subunit vaccine trial completed recruitment (approximately 20,000 individuals) across five high-burden countries, 11 months ahead of scheduled completion date. The first randomized controlled trial assessing DRTB-HDT host-directed therapy for DR-TB in adults (metformin + dovramilast), conducted at five international sites, is entering the late-stage readout phase. This synthesis of data, covering the period from 2015 through 2026, across six different dimensions includes molecular mechanisms of resistance, novel antimicrobial treatment modalities, host-directed therapy, immunity associated with regulatory compliance, adjuvants to vaccines, and the clinical translation of vaccine candidates. The Molecular-to-Translational continuum is used as a framework for the synthesis, with the regulatory immune function domain (T regulatory cells, myeloid-derived suppressor cells, and check-point axes) linking all five domains. Our central hypothesis is that drug resistance evolution of the microbe and failure of the host to maintain regulatory immunity are interdependent and create a bidirectional relationship with each other. We have identified nine major research gaps, with milestone dates from 2026 to 2030, based on unresolved controversies regarding the bedaquiline resistance catalog and the acquisition versus transmission narrative.
Related
- New strategies for the treatment of tuberculosis: research progress and clinical translation in immune modulation and inflammation control
- Synergistic strategies of tumor ablation and immunotherapy in hepatocellular carcinoma: mechanisms, clinical translation, and perspectives
- Inflammation and wound healing: a comprehensive overview of mechanisms, therapeutic strategies, and translational perspectives
- Challenges of Using a Bedaquiline-Based Regimen to Treat Multidrug-Resistant Tuberculosis in Pregnancy
- Machine Learning and Deep Learning for Early Disease Detection Across Modalities: A Comprehensive Review of Methods, Applications, and Clinical Translation
BibTeX
@article{yao2026novel,
title = {{Novel strategies against drug-resistant tuberculosis: a comprehensive review from molecular mechanisms to clinical translation}},
author = {Mingxiao Yao and Bo Pang and Ling Tian and Shuo Wang and Pengxiang Huang and Bingqin Dai and Zengqiang Kou and Shengyang Zhang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1912284},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1912284/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Novel strategies against drug-resistant tuberculosis: a comprehensive review from molecular mechanisms to clinical translation
AU - Mingxiao Yao
AU - Bo Pang
AU - Ling Tian
AU - Shuo Wang
AU - Pengxiang Huang
AU - Bingqin Dai
AU - Zengqiang Kou
AU - Shengyang Zhang
PY - 2026
DA - 2026/10/21
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1912284
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1912284/full
AB - In 2023, an estimated 13% of worldwide deaths resulting from antimicrobial resistance (AMR) were due to drug-resistant TB (DR-TB). The World Health Organization (WHO) documented a dramatic, sixfold increase in the number of patients treated with 6-month all-oral (BPaLM) regimens, from 5,653 patients in 2023, to 34,000 patients by 2024, while also documenting an emergence of bedaquiline resistance in real-world cohorts and a lack of efficacy of BCG revaccination in the BCG-PRIME Phase 2b trial against sustained Mycobacterium tuberculosis infection. Concurrently, the M72/AS01E subunit vaccine trial completed recruitment (approximately 20,000 individuals) across five high-burden countries, 11 months ahead of scheduled completion date. The first randomized controlled trial assessing DRTB-HDT host-directed therapy for DR-TB in adults (metformin + dovramilast), conducted at five international sites, is entering the late-stage readout phase. This synthesis of data, covering the period from 2015 through 2026, across six different dimensions includes molecular mechanisms of resistance, novel antimicrobial treatment modalities, host-directed therapy, immunity associated with regulatory compliance, adjuvants to vaccines, and the clinical translation of vaccine candidates. The Molecular-to-Translational continuum is used as a framework for the synthesis, with the regulatory immune function domain (T regulatory cells, myeloid-derived suppressor cells, and check-point axes) linking all five domains. Our central hypothesis is that drug resistance evolution of the microbe and failure of the host to maintain regulatory immunity are interdependent and create a bidirectional relationship with each other. We have identified nine major research gaps, with milestone dates from 2026 to 2030, based on unresolved controversies regarding the bedaquiline resistance catalog and the acquisition versus transmission narrative.
SN - 1664-3224
ER -